HBP Share Price

Open 1.35 Change Price %
High 1.40 1 Day -0.06 -4.38
Low 1.31 1 Week -0.02 -1.50
Close 1.31 1 Month -0.14 -9.66
Volume 36700 1 Year -0.59 -31.05
52 Week High 2.25
52 Week Low 1.20
HBP Important Levels
Resistance 2 1.39
Resistance 1 1.36
Pivot 1.34
Support 1 1.26
Support 2 1.23
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
IVN 4.97 2.26%
KAT 0.61 27.08%
KAT 0.61 27.08%
YRI 3.90 -3.47%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
KAT 0.61 27.08%
KAT 0.61 27.08%
PWC 0.10 25.00%
PWC 0.10 25.00%
IMP 0.11 22.22%
IMP 0.11 22.22%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
CTU-A 0.19 -9.52%
RKN 1.40 -8.50%
RKN 1.40 -8.50%
BUI 4.52 -7.76%
BUI 4.52 -7.76%
BUI 4.52 -7.76%
RIC 11.25 -7.71%
RIC 11.25 -7.71%
RIC 11.25 -7.71%
More..

Helix BioPharma Corp (TSE: HBP)

HBP Technical Analysis 5
As on 21st Feb 2017 HBP Share Price closed @ 1.31 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.80 & Strong Sell for SHORT-TERM with Stoploss of 1.47 we also expect STOCK to react on Following IMPORTANT LEVELS.
HBP Target for February
1st Target up-side 1.59
2nd Target up-side 1.66
3rd Target up-side 1.73
1st Target down-side 1.39
2nd Target down-side 1.32
3rd Target down-side 1.25
HBP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.helixbiopharma.com
HBP Address
HBP
305 Industrial Parkway South
Unit 3
Aurora, ON L4G 6X7
Canada
Phone: 905-841-2300
Fax: 905-841-2244
HBP Latest News
Helix BioPharma Corp. Announces Fiscal 2016 Results   Marketwired (press release)   - 01st Nov 16
Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR ...   Marketwired (press release)   - 20th Oct 16
Helix BioPharma Corp. Announces New Director Appointment   Marketwired (press release)   - 07th Sep 16
Helix BioPharma Corp. Opens the Market   MarketWatch   - 26th May 16
First Patient Dosed in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer   Marketwired (press release)   - 11th May 16
First Patient Enrolled in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer   Marketwired (press release)   - 28th Apr 16
Helix BioPharma Corp. Announces CEO Change   Marketwired (press release)   - 30th Mar 16
Helix BioPharma Corp. Reports on Advancement of Its Lung Cancer Drug Candidate ...   Marketwired (press release)   - 04th Mar 16
Monday Deal Review - November 3, 2015   Proactive Investors USA & Canada (blog)   - 04th Nov 15
BIO Announces Presenting Companies for 14   Business Wire (press release)   - 03rd Sep 15
Interactive Technical Analysis Chart Helix BioPharma Corp ( HBP TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Helix BioPharma Corp
HBP Business Profile
Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is based in Aurora, Canada.